It’s been a good year for GlaxoSmithKline. Just one year after its Shingrix shingles vaccine was approved by the FDA, the drug is in such high demand that availability has become an issue and the drug manufacturer is ramping up production to meet the growing need.
“We understand that this is a challenging situation to manage, and GSK is fully committed to expediting resupply throughout 2018. Going forward, providers and ...
continue reading...